Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19092139 | 0.84 | KMT2A (0.62) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL3971438 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL3303527 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL8200466 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL565301 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL699639 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL10724066 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL8203532 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL4537086 | 0.80 | PKM (0.88) | KMT2AMEN1HTTPKMALDH1A1 | |
| SCHEMBL14251942 | 0.80 | PKM (0.66) | KMT2AMEN1HTTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828316-B2 | Antiallergens | KOWA CO., LTD. (JP) | 2004-12-07 | — | — | US | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | KMT2A 439/4885MEN1 3292/4885HTT 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.